Life Edit Therapeutics
Hannah Wiedner, PhD, currently holds the position of Scientist I in Computational Biology at Life Edit Therapeutics since May 2023. Prior to this role, Hannah was a Graduate Student Researcher at the University of North Carolina at Chapel Hill from August 2017 to February 2023, focusing on RNA binding proteins and epigenetic modifications in muscle and heart development. This experience included analyzing transcriptomic datasets and defining splice-isoforms' functions. Hannah also co-founded the outreach program Shadow A Scientist, facilitating scientific shadowing experiences for over 350 students, and has interned in therapeutic discovery at StrideBio, Inc., as well as worked in various research and environmental roles. Educational qualifications include a Bachelor of Science in Neuroscience and Biochemistry & Molecular Biology from the University of Miami and a PhD from the University of North Carolina at Chapel Hill.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.